Population-based incidence of psoriasis vulgaris in Germany: analysis of national statutory insurance data from 65 million population.
Age-specific
Age-standardized
Germany
Incidence
Population-based
Psoriasis vulgaris
Sex-specific
Journal
Archives of dermatological research
ISSN: 1432-069X
Titre abrégé: Arch Dermatol Res
Pays: Germany
ID NLM: 8000462
Informations de publication
Date de publication:
04 Jan 2024
04 Jan 2024
Historique:
received:
12
09
2023
accepted:
05
12
2023
revised:
10
10
2023
medline:
4
1
2024
pubmed:
4
1
2024
entrez:
4
1
2024
Statut:
epublish
Résumé
Information on the population-based incidence of psoriasis vulgaris was limited. This study was to provide a comprehensive understanding of the age-specific and sex-specific incidence of psoriasis vulgaris in Germany. The data were obtained in the context of a morbidity-based risk adjustment by statutory health insurance companies in Germany, comprising information regarding 65 million population. Psoriasis vulgaris diagnoses were made and coded according to the 10th edition of the International Statistical Classification of Diseases and Related Health Problems. Age-specific and sex-specific incidences were calculated using data from 2009 to 2011. There was a rise in the age- and sex-specific incidences of psoriasis vulgaris through midlife, reaching a peak at the age of 60 and subsequently declining for both genders. The peak incidence for men, at 130 cases per 100,000 person-years, slightly exceeded the peak incidence for women of 117 per 100,000 person-years. An increase in the overall incidence rate can also be observed over the course of the three-year period covered by the data. Considerable variations in the age- and sex-specific incidences of psoriasis vulgaris can be seen across the lifespan. Nevertheless, the overall age-standardized incidence for the German population was low compared to other European countries.
Identifiants
pubmed: 38175227
doi: 10.1007/s00403-023-02796-y
pii: 10.1007/s00403-023-02796-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
65Informations de copyright
© 2024. The Author(s).
Références
Egeberg A, Skov L, Gislason GH, Thyssen JP, Mallbris L (2017) Incidence and prevalence of psoriasis in Denmark. Acta Derm Venereol 97:808–812. https://doi.org/10.2340/00015555-2672
doi: 10.2340/00015555-2672
pubmed: 28417141
Springate DA, Parisi R, Kontopantelis E, Reeves D, Griffiths CE, Ashcroft DM (2017) Incidence, prevalence and mortality of patients with psoriasis: a U.K. population-based cohort study. Br J Dermatol 176:650–658. https://doi.org/10.1111/bjd.15021
doi: 10.1111/bjd.15021
pubmed: 27579733
Eder L, Widdifield J, Rosen CF, Cook R, Lee KA, Alhusayen R et al (2019) Trends in the prevalence and incidence of psoriasis and psoriatic arthritis in Ontario, Canada: a population-based study. Arthritis Care Res (Hoboken) 71:1084–1091. https://doi.org/10.1002/acr.23743
doi: 10.1002/acr.23743
pubmed: 30171803
Bauhoff S, Fischer L, Göpffarth D, Wuppermann AC (2017) Plan responses to diagnosis-based payment: evidence from Germany’s morbidity-based risk adjustment. J Health Econ 56:397–413. https://doi.org/10.1016/j.jhealeco.2017.03.001
doi: 10.1016/j.jhealeco.2017.03.001
pubmed: 29248063
Rommel A, Schmidt C (2018) Germany’s data transparency regulations—potential, developments and RKI federal health reporting activities. J Health Monit 3:11. https://doi.org/10.17886/rki-gbe-2018-056
Federal Office for Social Security (2023) Morbidity-Based Risk Structure Compensation (morbiditätsorientierter Risikostrukturausgleich, Morbi-RSA). https://www.bundesamtsozialesicherung.de/de/themen/risikostrukturausgleich/rsa-einfach-erklaert/ (In German). Accessed 9 Oct, 2023
Nast A, Boehncke WH, Mrowietz U, Ockenfels HM, Philipp S, Reich K et al (2012) German S3-guidelines on the treatment of psoriasis vulgaris (short version). Arch Dermatol Res 304:87–113. https://doi.org/10.1007/s00403-012-1214-8
doi: 10.1007/s00403-012-1214-8
pubmed: 22350179
German Institute for Medical Documentation and Information (DIMDI) (2023) Psoriasis vulgaris (Papulosquamous skin diseases [L40-L45]) diagnoses according to the 10th edition of the International Statistical Classification of Diseases and Related Health Problems (WHO Version 1.3). https://www.dimdi.de/static/de/klassifikationen/icd/icd-10-who/kode-suche/htmlamtl/index.htm?gm05.htm + (In German). Accessed 8 Oct, 2023
Pezzolo E, Cazzaniga S, Colombo P, Chatenoud L, Naldi L (2019) Psoriasis incidence and lifetime prevalence: suggestion for a higher mortality rate in older age-classes among psoriatic patients compared to the general population in Italy. Acta Derm Venereol 99:400–403. https://doi.org/10.2340/00015555-3130
doi: 10.2340/00015555-3130
pubmed: 30673108
Deike M, Brinks R, Meller S, Schneider M, Sewerin P (2021) Risk of psoriatic arthritis depending on age: analysis of data from 65 million people on statutory insurance in Germany. RMD Open. https://doi.org/10.1136/rmdopen-2021-001975
doi: 10.1136/rmdopen-2021-001975
pubmed: 34862312
pmcid: 8647537
Brinks R, Landwehr S, Icks A, Koch M, Giani G (2013) Deriving age-specific incidence from prevalence with an ordinary differential equation. Stat Med 32:2070–2078. https://doi.org/10.1002/sim.5651
doi: 10.1002/sim.5651
pubmed: 23034867
Brinks R, Landwehr S (2015) A new relation between prevalence and incidence of a chronic disease. Math Med Biol 32:425–435. https://doi.org/10.1093/imammb/dqu024
doi: 10.1093/imammb/dqu024
pubmed: 25576933
pmcid: 4684690
Ahlehoff O, Gislason GH, Charlot M, Jørgensen CH, Lindhardsen J, Olesen JB et al (2011) Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 270:147–157. https://doi.org/10.1111/j.1365-2796.2010.02310.x
doi: 10.1111/j.1365-2796.2010.02310.x
pubmed: 21114692
Schonmann Y, Ashcroft DM, Iskandar IYK, Parisi R, Sde-Or S, Comaneshter D et al (2019) Incidence and prevalence of psoriasis in Israel between 2011 and 2017. J Eur Acad Dermatol Venereol 33:2075–2081. https://doi.org/10.1111/jdv.15762
doi: 10.1111/jdv.15762
pubmed: 31237370
Sewerin P, Brinks R, Schneider M, Haase I, Vordenbäumen S (2019) Prevalence and incidence of psoriasis and psoriatic arthritis. Ann Rheum Dis 78:286–287. https://doi.org/10.1136/annrheumdis-2018-214065
doi: 10.1136/annrheumdis-2018-214065
pubmed: 30242033
Icen M, Crowson CS, McEvoy MT, Dann FJ, Gabriel SE, Maradit Kremers H (2009) Trends in incidence of adult-onset psoriasis over three decades: a population-based study. J Am Acad Dermatol 60:394–401. https://doi.org/10.1016/j.jaad.2008.10.062
doi: 10.1016/j.jaad.2008.10.062
pubmed: 19231638
pmcid: 3028518
Pina Vegas L, Sbidian E, Penso L, Claudepierre P (2021) Epidemiologic study of patients with psoriatic arthritis in a real-world analysis: a cohort study of the French health insurance database. Rheumatology (Oxford) 60:1243–1251. https://doi.org/10.1093/rheumatology/keaa448
doi: 10.1093/rheumatology/keaa448
pubmed: 32911531
Brinks R, Tönnies T, Hoyer A (2021) Impact of diagnostic accuracy on the estimation of excess mortality from incidence and prevalence: simulation study and application to diabetes in German men. F1000Res 10:49. https://doi.org/10.12688/f1000research.28023.1
Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM (2020) National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ 369:m1590. https://doi.org/10.1136/bmj.m1590
doi: 10.1136/bmj.m1590
pubmed: 32467098
pmcid: 7254147
Iskandar IYK, Parisi R, Griffiths CEM, Ashcroft DM (2021) Systematic review examining changes over time and variation in the incidence and prevalence of psoriasis by age and gender. Br J Dermatol 184:243–258. https://doi.org/10.1111/bjd.19169
doi: 10.1111/bjd.19169
pubmed: 32358790
Ritchlin CT, Colbert RA, Gladman DD (2017) Psoriatic arthritis. N Engl J Med 376:957–970. https://doi.org/10.1056/NEJMra1505557
doi: 10.1056/NEJMra1505557
pubmed: 28273019
World Health Organization (2016) Global report on psoriasis. World Health Organization. https://apps.who.int/iris/handle/10665/204417 . Accessed 8 Oct, 2023
Federal Institute for Pharmaceuticals and Medical Products (2023) Health Research Data Center (Forschungsdatenzentrum Gesundheit). https://www.forschungsdatenzentrum-gesundheit.de/faq/faq-antrag-02/ (In German). Accessed 8 Oct, 2023